Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Competitive TresibaⓇ label across all three triad markets Profile TresibaⓇ label characteristics in triad markets US Half-life of 25 hours and duration of action of at least 42 hours Day to day variability of 20% Europe • • Duration of action beyond 42 hours • Four times lower day-to-day variability vs insulin glargine • Efficacy Safety Convenience • . Non-inferior HbA1c reduction Numerically greater FPG reduction Numerically lower insulin dose¹ Overall safety consistent with insulin Hypoglycaemia rates for TresibaⓇ, but not comparator • Injection any time of day Up to 80 and 160 units per injection • Non-inferior HbA1c reduction . Numerically greater FPG reduction • • Overall safety consistent with insulin Lower rate of overall and nocturnal hypoglycaemia Adjusting injection time when needed Up to 80 and 160 units per injection 1 Observed in majority of the trials changing diabetes® Slide 61 Japan Duration of action up to 26 hours in Japanese patients Four times lower day-to-day variability vs insulin glargine • Non-inferior HbA1c reduction • Numerically greater FPG reduction • . Overall safety consistent with insulin Lower rate of nocturnal hypoglycaemia in Asian subjects In case of missed dose take as soon as possible novo nordisk

View entire presentation